Ascendis Pharma shares are trading lower after the company reported worse-than-expected Q2 sales results and cut its FY24 SKYTROFA revenue guidance.
Portfolio Pulse from Benzinga Newsdesk
Ascendis Pharma's shares declined following disappointing Q2 sales results and a reduction in FY24 revenue guidance for its SKYTROFA product.
September 04, 2024 | 11:44 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Ascendis Pharma's shares fell due to worse-than-expected Q2 sales and a cut in FY24 revenue guidance for SKYTROFA, indicating potential challenges in sales performance.
The company's shares are likely to decline in the short term due to the negative earnings report and reduced revenue guidance, which suggests potential issues with product sales or market conditions.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100